

Author Index

VOLUME 21, 2003

Adamson, David, 223

Arici, Aydin, 109, 135, 165

Azziz, Ricardo, 295

Barnes, Randall B., 285

Bossuyt, Patrick M.M., 17

Bradshaw, Karen D., 327, 339, 353

Bruner-Tran, Kaylon L., 155

Bulun, Serdar E., 125

Carr, Bruce R., 1, 107, 263, 325

Collins, John A., 3, 49, 95

Coutifaris, Christos, 265, 317

Davis, O.K., 65

Daya, Salim, 73

Debrock, Sophie, 243

D'Hooghe, Thomas M., 243

Donnez, Jacques, 235

Driscoll, Deborah A., 301

Duleba, Antoni J., 193

Ehrmann, David A., 277

Eijkemans, M.J.C., 39

Evers, Johannes L.H., 9, 17

Fauser, B.C.J.M., 39

Fazleabas, Asgerally T., 255

Foster, Warren G., 145

Fritz, Marc A., 27

Garcia-Velasco, Juan A., 165

Garrido, Nicolás, 183

Gell, Jennifer S., 375

Giudice, Linda C., 119

Groll, Jeremy M., 27

Gurates, Bilgin, 125

Guzick, David, 309

Habbema, J.D.F., 39

Hastings, Julie M., 255

Heroux, Kimberly, 389

Hill, Joseph A., 243

Hoffman, Barbara, 353

Hughes, Edward G., 55

Jabara, Sami, 317

Jadoul, Pascale, 235

Kakarla, Nirupama, 339

Kashyap, S., 65

Kass-Wolff, Jane, 329

Kennedy, Stephen, 111

Land, Jolande A., 9

Legro, Richard S., 267

Lijmer, Jeroen G., 17

Liu, James H., 5

Meuleman, Christel, 243

Minjarez, Debra A., 363

Mol, Ben W., 9, 17

Moran, Carlos, 295

Neithardt, Adrienne B., 285

Olive, David L., 209

Osteen, Kevin G., 155

Pellicer, Antonio, 183

Pirard, Céline, 235

Remohí, José, 183

Rier, Sherry, 145

Rychlik, Daniel, 277

Schlesselman, James J., 95

Seli, Emre, 135

Simón, Carlos, 183

Smets, Mireille, 235

Spaczynski, Robert Z., 193

Squifflet, Jean, 235

Sukalich, Sara, 309

Sulak, Patricia J., 399

Van Steirteghem, André, 49

Van Voorhis, Bradley J., 85

Wilson, Ellen E., 329

Witz, Craig A., 173

Yeaman, Grant R., 155



Subject Index

VOLUME 21, 2003

Absolute numbers, in randomized clinical trials (RCT), clinical research *vs.* medical practice, 55–64

Acanthosis nigricans, polycystic ovary syndrome (PCOS) and, 271–273

Acne, polycystic ovary syndrome (PCOS), pharmacologic treatment, 277–282

Acquired immunodeficiency syndrome (AIDS), in adolescent patients, 407–408

Adolescent patients. *See also* Pediatric gynecology
abnormal bleeding in, 363–372
contraceptive choices for chronically ill patients, 389–398
delayed puberty and amenorrhea, 353–361
polycystic ovary syndrome (PCOS), 301–306
pubertal developmental disorders, 339–350
sexually transmitted disease (STD) in, 399–411

Adrenal hyperplasia, in polycystic ovary syndrome (PCOS) patients, 295–299

Amenorrhea, delayed puberty and, 353–361

Androgen excess. *See* Hyperandrogenism

Androgen receptor antagonists, for polycystic ovary syndrome (PCOS) patients, 289–291

Angiogenesis inhibitors, endometriosis therapy using, 212–218

Animal models, endometriosis research, 150–151, 255–260

Anovulation
abnormal bleeding in adolescents, 363–372
clomiphene citrate therapy, outcome predictions, 39–46
polycystic ovary syndrome (PCOS), 267–273

Antiandrogens, polycystic ovary syndrome (PCOS), hirsutism diagnosis and management, 285–291

Apoptosis, endometriosis pathogenesis and, 165–170

Aromatase, endometriosis pathophysiology, 125–132

Aromatase inhibitors
endometriosis pathophysiology, 125–132
endometriosis therapy using, 212–218

Assisted reproduction therapy (ART), intracytoplasmic sperm injection *vs.* in vitro fertilization, evidence-based research, 49–54

Autoantibodies, endometriosis and, 137–141

Bcl-2/bax genes, apoptosis and endometriosis pathogenesis, 165–170

Bias, causation study guidelines and, 73–83

Bioinformatics, endometriosis research and, 260

Blood dyscrasias, abnormal bleeding in adolescents and, 365–370

Breast disease, contraception for medically ill adolescent patients and risk of, 390–398

Cadherins, endometriosis and, 175–178

CA-125 marker, endometriosis diagnosis, 193–202

Cardiovascular health
contraception for medically ill adolescent patients, 390–398
polycystic ovary syndrome (PCOS) and, 309–314

Case control studies
causation study guidelines and, 73–83
diagnostic studies using, 20–25

Causation studies, guidelines for, 73–83

cDNA microarray analysis, endometriosis research and, 259–260

Cell adhesion molecules (CAMs), endometriosis and, 173–179
apoptosis pathways, 168–170

Cervicitis, abnormal bleeding in adolescents and, 365–370

Chlamydia, in adolescent patients, 402–403

Chlamydia antibody test (CAT), evidence-based diagnosis and, 9–14

Clinical research. *See also* Randomized clinical trials (RCT)
diagnostic research, evidence-based strategies, 9–14
evidence-based search strategies, 5–8
medical therapy for endometriosis and, 209–218
randomized clinical trials (RCT) and medical practice *vs.*, 55–64
systematic review and meta-analysis of, 95–104

Clomiphene citrate therapy, ovulation induction, outcome predictions, 39–46

Coagulation disorders, polycystic ovary syndrome (PCOS) patients and, 311–314

Cohort studies
causation study guidelines, 73–83
diagnostic studies using, 20–25

Condom use, sexually transmitted disease (STD) in adolescents and, 399–411

Condyloma acuminata
abnormal bleeding in adolescents and, 366–370
in pediatric patients, 336–337

Confounding variables, causation study guidelines, 73–83

Contraception. *See also* Oral contraceptives
for medically ill adolescent patients, 389–398
sexually transmitted disease (STD) in adolescents and, 399–411

Contrasexual development, in pediatric patients, 349–350

Coronary heart disease (CHD)
contraception for medically ill adolescent patients, 390–398
polycystic ovary syndrome (PCOS) and risk of, 309–314
prognosis studies, literature evaluation for, 27–35

Cost-effectiveness, economics studies evaluation, 85–92
Cytokines
 endometriosis pathophysiology and, 135–141
 matrix metalloproteinases, endometriosis pathophysiology, 155–160

Danazol, endometriosis therapy using, 209–218
Delayed puberty, amenorrhea and, 353–361
Diabetes mellitus, contraception for medically ill adolescent patients, 390–398. *See also* Type 2 diabetes mellitus
Diagnostic studies
 characteristics of, 17–25
 endometriosis, 193–202
 evidence-based guidelines for, 9–14
 pediatric gynecology, 329–337
 polycystic ovary syndrome (PCOS), 267–273
 21-hydroxylase-deficient nonclassic adrenal hyperplasia, differential diagnosis, 295–299

Diagnostic testing, causation study guidelines and, 73–83
Differential diagnoses
 endometriosis, 193–202
 evidence-based strategies for, 9–14
 polycystic ovary syndrome (PCOS), 267–273
 21-hydroxylase-deficient nonclassic adrenal hyperplasia and, 295–299

Dioxins/dioxin-like polychlorinated biphenyls, endometriosis pathogenesis and, 145–151

DNA markers, endometriosis genetics, 111–117

Ductal system development, Müllerian anomalies, 377–387

Dyslipidemia
 contraception for medically ill adolescent patients, 390–398
 polycystic ovary syndrome (PCOS) and cardiovascular health, 309–314

Economics studies, evaluation of, 85–92

Ectopic endometrium
 gene/protein expression, 122–123
 research issues involving, 255–260

Ectopic hormone production, pubertal developmental disorders and, 349

Embryo status, in endometriosis, 183–189

Endocrine system
 endometriosis pathophysiology and, 135–141
 environmental contaminants and endometriosis, 145–151

Endometriomas, surgical management of, 223–230

Endometriosis
 apoptosis and pathogenesis of, 165–170
 cell-adhesion molecules, 173–179
 differential diagnosis, 193–202
 environmental dioxins and, 145–151
 future research issues, 255–260
 genetics and positional cloning, 111–117
 hormonal factors in, 125–132
 immune/endocrine system interaction, 135–141
 matrix metalloproteinases and, 155–160
 medical therapy, 209–218
 pathogenesis, genomic studies, 119–123
 subfertility and, 243–251
 surgical management of, 223–230

surgical management of, pre- and post-surgical protocols, 235–240
uterine and ovarian function, 183–189

Environmental contaminants
 endometriosis and, 145–151
 matrix metalloproteinases, endometriosis pathophysiology, 155–160

Estradiol, endometriosis pathophysiology, 125–132

Estrogen
 endometriosis pathophysiology, 125–132
 endometriosis therapy using, 212–218
 matrix metalloproteinases, endometriosis pathophysiology, 155–160

Estrogen receptor ($\text{ER}\beta$), endometriosis research and, 255–260

Estrone, endometriosis pathophysiology, 125–132

Eutopic endometrium
 apoptosis and endometriosis pathogenesis, 165–170
 endometriosis and function of, 186–189
 gene/protein expression, 122–123
 research issues involving, 255–260

Evidence-based research guidelines
 diagnostic issues, 9–14
 prognosis studies, 27–35
 therapeutic options and, 5–8
 in vitro fertilization trials, 49–54

Exercise/dieting, abnormal bleeding in adolescents and, 371–372

Extracellular matrix (ECM), endometriosis and
 apoptosis pathways, 165–170
 cell adhesion molecules (CAMs), 173–179

Familial male precocious puberty, pathophysiology, 348–349

Fas/fas ligands, apoptosis and endometriosis pathogenesis, 165–170

Femal genital anatomy
 delayed puberty and defects in, 359–361
 Müllerian anomalies, 375–387
 in pediatric patients, 329–333
 pubertal developmental disorders and, 340–343

Fertility drugs, ovarian cancer risk and, 65–71

Genetics studies. *See also* Proteomics
 apoptosis and endometriosis pathogenesis, 165–170
 endometriosis, positional cloning, 111–117

Genital herpes, in adolescent patients, 405–406

Genital human papillomavirus, in adolescent patients, 406–407

Genomics, endometriosis pathogenesis, 119–123

Gestrinone, endometriosis therapy using, 211–218

Glucocorticoids, for polycystic ovary syndrome (PCOS) patients, 289–291

GnRH agonists/antagonists
 endometriosis therapy using, 211–218
 for polycystic ovary syndrome (PCOS) patients, 289–291

Gonadotropin-dependent precocious puberty, 345–347

Gonadotropin-independent precocious puberty, 347–349

Gonadotropin-releasing hormone (GnRH), pubertal developmental disorders, 339–350

Gonorrhea, in adolescent patients, 403–404

Hair removal, polycystic ovary syndrome (PCOS), hirsutism diagnosis and management, 285–291

Hirsutism, polycystic ovary syndrome (PCOS)
adolescent patients, 301–306
diagnosis and management, 285–291
pharmacologic treatment, 277–282

Hormone function
delayed puberty and, 353–361
endometriosis pathophysiology and, 125–132
medical therapy for endometriosis and, 209–218
polycystic ovary syndrome (PCOS), adolescent patients, 301–306
pubertal developmental disorders, 339–350

Human immunodeficiency virus (HIV), in adolescent patients, 407–408

Humoral immune response, endometriosis and, 137–141

21-Hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH), polycystic ovary syndrome (PCOS), differential diagnosis, 295–299

17 β -Hydroxysteroid dehydrogenase (HSD) type 2, endometriosis pathophysiology, 125–132

Hyperandrogenism, polycystic ovary syndrome (PCOS), 267–273
adrenal hyperplasia and, 295–299
hirsutism diagnosis and management, 285–291

Hypercoagulation, contraception for medically ill adolescent patients, 390–398

Hypergonadotropic hypogonadism, delayed puberty and, 356–361

Hyperprolactinemia, abnormal bleeding in adolescents and, 371–372

Hypertension
contraception for medically ill adolescent patients, 390–398
in polycystic ovary syndrome (PCOS) patients, 310–314

Hypogonadotropic hypogonadism, delayed puberty and, 355–361

Hypothalamic-pituitary-ovarian (HPO) axis
abnormal bleeding in adolescents and, 363–372
precocious puberty diagnosis and pathophysiology, 339–350

Hypothyroidism, abnormal bleeding in adolescents and, 371–372

Hysterosalpingography, evidence-based diagnostic strategies, 9–14

Imaging studies, endometriosis diagnosis, 193–202

Immune response
endometriosis pathophysiology and, 135–141
environmental contaminants and endometriosis, 145–151

Immunoglobulin superfamily, endometriosis and, 175–178

Immunomodulation, endometriosis research and, 255–260

Imperforate hymen, in pediatric patients, 333–335

Implantation mechanisms, endometriosis pathogenesis, 119–123

Index tests, diagnostic studies and, 17–25

Infertility. *See also* In vitro fertilization/embryo transfer (IVF-ET); Subfertility
economics studies evaluation, 85–92
endometriosis, medical therapy for, 209–218

in polycystic ovary syndrome (PCOS) patients, 279–283, 317–323

surgical management of endometriosis and, 223–230
uterine and ovarian function with endometriosis and, 183–189

Inflammatory disease, endometriosis research and, 255–260

Inheritance studies, polycystic ovary syndrome (PCOS), 298–299

Insulin resistance
polycystic ovary syndrome (PCOS), 267–273
cardiovascular health and, 309–314

polycystic ovary syndrome (PCOS), pharmacologic treatment, 277–282

Integrins, endometriosis and, 174–178

"Intent to treat" analysis, randomized clinical trials (RCT) and clinical research *vs.*, 55–64

Intracytoplasmic sperm injection (ICSI), *vs.* in vitro fertilization, evidence-based research, 49–54

In vitro fertilization/embryo transfer (IVF-ET)
clinical trials, evidence-based research guidelines, 49–54
economics studies evaluation, 85–92
endometriosis pathogenesis, 119–123
ovarian and uterine function in endometriosis and, 183–189
ovarian cancer risk and, 65–71
in polycystic ovary syndrome (PCOS) patients, 317–323

Kallmann syndrome, delayed puberty and, 355–361

Klinefelter's syndrome, delayed puberty and, 357–361

Labial adhesions, in pediatric patients, 333–335

Laparoscopy
endometriosis diagnosis, 193–202
evidence-based diagnostic strategies using, 9–14

Lateral fusion, Müllerian anomalies and, 385–387

Likelihood ratios, in diagnostic studies, 17–25

Literature resources
evaluation of, for prognosis strategies, 27–35
evidence-based search strategies, 5–8
ovarian cancer risk and fertility drugs, evaluation of literature on, 65–71
systematic review and meta-analysis of, 95–104

Luteinizing hormone, polycystic ovary syndrome (PCOS) and in vitro fertilization, 318–323

Lymphocytes, endometriosis and, 137–141

Matrix metalloproteinases
endometriosis pathophysiology and, 155–160
inhibitors, endometriosis therapy with, 213–218

McCune-Albright syndrome, in pediatric patients, 347–348

Medical practices and procedures
economics studies evaluation and, 85–92
endometriosis therapy, 209–218
randomized clinical trials (RCT) and clinical research *vs.*, 55–64
systematic review and meta-analyses concerning, 95–104

Medical search engine design, evidence-based search strategies, 5–8

Menorrhagia, abnormal bleeding in adolescents, 363–372

Menstruation cycle
abnormal bleeding in adolescents, 363–372
delayed puberty and amenorrhea, 353–361
endometrial environment during, 159–160
matrix metalloproteinase expression during, 155–160
polycystic ovary syndrome (PCOS), adolescent patients, 301–306
retrograde menstruation, endometriosis pathophysiology, 135–141

Mental disability, contraception for medically ill adolescent patients, 390–398

Meta-analysis, evaluation of, 95–104

Metformin, prognosis studies, literature evaluation for, 27–35

Molecular targeting, medical therapy for endometriosis and, 209–218

Monocyte chemotactic protein-1 (MCP-1), endometriosis and, 137–141

Monthly fecundity rate (MFR), subfertility and endometriosis, 243–251

Müllerian anomalies, diagnosis and pathophysiology, 375–387
abnormal bleeding in adolescents and, 367–370

Natural killer cells, endometriosis pathophysiology, 135–141

Normogonadotropic oligoamenorrheic infertility, clomiphene citrate therapy, outcome predictions, 39–46

Obesity, polycystic ovary syndrome (PCOS) patients and, 309–314

Odds ratios, causation study guidelines, 73–83

Oligomenorrhea, polycystic ovary syndrome (PCOS) therapy, 277–282

Oocyte alteration, in endometriosis, 183–189

Oocyte implantation, in polycystic ovary syndrome (PCOS) patients, 317–323

Oral contraceptives
endometriosis therapy using, 210–218
for medically ill adolescent patients, 389–398
for polycystic ovary syndrome (PCOS) patients, 288–291

Oral glucose tolerance test (OGTT), in polycystic ovary syndrome (PCOS) patients, 267–273, 277–283

Outcome prediction, economics studies evaluation and, 85–92

Ovarian cancer, fertility drugs and, 65–71

Ovarian endometriosis, surgical management of, 235–240

Ovarian function
abnormal bleeding in adolescents and, 369–371
in endometriosis, 183–189
genetic factors in endometriosis and, 111–117
polycystic ovary syndrome (PCOS) and, 268–273

Ovarian hyperstimulation syndrome, in polycystic ovary syndrome (PCOS) patients, 317–323

Ovarian suppression, endometriosis management, surgical therapy *vs.*, 223–231

Ovulation induction
clomiphene citrate therapy, outcome predictions, 39–46
ovarian cancer risk and, 65–71

Pediatric gynecology
abnormal bleeding in adolescents, 363–372
assessment strategies and issues, 329–337

contraception for medically ill adolescent patients, 389–398
delayed puberty and amenorrhea, 353–361
Müllerian anomalies, 375–387
pubertal developmental disorders, 339–350
sexually transmitted diseases (STDs), 399–411

Pelvic examination, endometriosis diagnosis and, 193–202

Pelvic inflammatory disease (PID), in adolescent patients, 404–405

Pelvic pain
medical therapy for endometriosis and, 209–218
surgical management of endometriosis and, 223–230

Pentoxifylline, endometriosis therapy using, 213–218

Peritoneal fluid, endometriosis and function of, 184–189

Pharmacology, polycystic ovary syndrome (PCOS) therapy, 277–282

PICO (Patient-Intervention-Comparison-Outcome)
research strategy, differential diagnosis and, 9–14

Polycystic ovary syndrome (PCOS)
adolescent patients, 301–306
cardiovascular health and, 309–314
diagnostic criteria, 267–273
hirsutism diagnosis and management, 285–291
21-hydroxylase-deficient nonclassic adrenal hyperplasia, differential diagnosis, 295–299
pharmacologic therapy, 277–282
prognosis studies, literature evaluation for, 27–35
in vitro fertilization/embryo transfer (IVF-ET) and, 317–323

Positional cloning techniques, endometriosis genetics, 111–117

Postoperative protocols, surgical management of endometriosis, 235–240

Precocious puberty, diagnosis and pathophysiology, 339–350

Pregnancy, abnormal bleeding in adolescents and, 364–370

Pregnancy rates, subfertility and endometriosis, 243–251

Preoperative protocols, surgical management of endometriosis, 235–240

Prepubertal reproductive anatomy, assessment strategies and issues, 329–337

Prevalence studies, subfertility and endometriosis, 243–251

Progesterone
endometriosis pathophysiology, 125–132
matrix metalloproteinases, endometriosis pathophysiology, 155–160

Progesterone receptor, endometriosis pathophysiology, 125–132

Progesterogens, endometriosis therapy using, 210–218

Prognosis studies
evidence-based strategies and literature evaluation, 27–35
treatment outcome predictions, 39–46

Proinflammatory cytokines, matrix metalloproteinases, endometriosis pathophysiology, 155–160

Proportions, in randomized clinical trials (RCT), clinical research *vs.* medical practice, 55–64

Proteins, endometriosis and ECM proteins, 176–178

Proteomics. *See also* Genetics studies; Genomics
endometriosis pathogenesis, 119–123

Pubertal developmental disorders
delayed puberty and amenorrhea, 353–361
polycystic ovary syndrome (PCOS) in adolescence and, 301–306
precocious puberty, 339–350

Randomized clinical trials (RCT)
causation study guidelines, 73–83
in diagnostic studies, 17–25
medical practice *vs.* clinical research involving, 55–64
prognosis studies, literature evaluation for, 27–35
systematic review and meta-analysis of, 95–104
in vitro fertilization, evidence-based research, 49–54
RANTES cytokine, endometriosis and, 137–141
Reference tests, diagnostic studies and, 17–25
Relative risks, causation study guidelines, 73–83
Renal disease, contraception for medically ill adolescent patients, 390–398
Research protocols
endometriosis and subfertility, 245–251
endometriosis research, 255–260
environmental contaminants, 145–151
evidence-based research guidelines
diagnostic issues, 9–14
prognosis studies, 27–35
therapeutic options and, 5–8
in vitro fertilization trials, 49–54
literature evaluations
ovarian cancer risk and fertility drugs, evaluation of literature on, 65–71
systematic review and meta-analysis of, 95–104
Retrograde menstruation, endometriosis pathophysiology, 135–141
Risk difference, systematic review and meta-analysis of, 95–104
Rokitansky-Kuster-Hauser syndrome, Müllerian anomalies, 379–387
RU486, endometriosis therapy using, 211–218

Sampson's theory of retrograde menstruation, endometriosis pathophysiology and, 135–141
Selectins, endometriosis and, 175–178
Sensitivity in testing, diagnostic studies and, 17–25
Sexual abuse, pediatric gynecology and, 329–337
Sexual differentiation, Müllerian anomalies, 375–387
Sexually acquired hepatitis, in adolescent patients, 408–409
Sexually transmitted disease (STD), in adolescents, 399–411
Specificity in testing, diagnostic studies and, 17–25
Steroid hormones, endometriosis and, 258–260
Steroidogenesis, endometriosis pathophysiology, 125–132
Subfertility. *See also* Infertility
endometriosis and, 243–251

Surgical procedures
endometriosis diagnosis, 201–202
endometriosis management
medical therapy following, 216–218
pre- and post-surgical guidelines, 235–240
endometriosis therapy using, 223–230
Syphilis, in adolescent patients, 401–402
Systematic review, evaluation of, 95–104
Systemic lupus erythematosus (SLE), contraception for medically ill adolescent patients, 390–398

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD),
endometriosis pathogenesis and, 145–151
Therapeutic strategies, evidence-based guidelines for, 5–8
Thromboembolism history, contraception for medically ill adolescent patients, 390–398
Tissue inhibitors of metalloproteinases (TIMPs),
endometriosis and, 155–160
Transplantation theory, apoptosis and endometriosis pathogenesis, 165–170
Trichomoniasis, in adolescent patients, 400–401
Tubal factor subfertility, evidence-based diagnosis of, 9–14
Tumor necrosis factor (TNF)- α inhibitors, endometriosis therapy using, 212–218
Turner's syndrome, delayed puberty and, 357–361
Type 2 diabetes mellitus. *See also* Diabetes mellitus
Type 2 diabetes mellitus, polycystic ovary syndrome (PCOS) and, 277–282

Ultrasonography, polycystic ovary syndrome (PCOS), 267–273
Urethral prolapse, in pediatric patients, 336–337
Uterine function
abnormal bleeding in adolescents and, 367–370
in endometriosis, 183–189
endometriosis research and receptivity studies, 255–260
Müllerian anomalies, 375–387

Vaginal septum, Müllerian anomalies, 375–387
Vaginitis, abnormal bleeding in adolescents and, 366–370
Vascular endothelial growth factor (VEGF), endometriosis and, 141
Verification bias, in diagnostic studies, 21–25
Vertical fusion, Müllerian anomalies and, 383–387
Vulvitis, in prepubertal patients, 329–337
Vulvovaginitis, in prepubertal patients, 329–337

Y chromosome disorders, Müllerian anomalies, 375–387